Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
34.02
-4.07 (-10.69%)
At close: Apr 28, 2026, 4:00 PM EDT
34.28
+0.25 (0.75%)
Pre-market: Apr 29, 2026, 6:02 AM EDT
Qiagen Revenue
In the year 2025, Qiagen had annual revenue of $2.09B with 5.65% growth. Qiagen had revenue of $540.42M in the quarter ending December 31, 2025, with 3.69% growth.
Revenue (ttm)
$2.09B
Revenue Growth
+5.65%
P/S Ratio
3.37
Revenue / Employee
$366,666
Employees
5,700
Market Cap
7.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.09B | 111.79M | 5.65% |
| Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
| Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
| Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
| Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Charles River Laboratories International | 4.02B |
| Revvity | 2.86B |
| Medpace Holdings | 2.68B |
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| Guardant Health | 982.02M |
QGEN News
- 9 hours ago - Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 20 hours ago - Qiagen Transcript: Investor update - Transcripts
- 1 day ago - QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook - Business Wire
- 12 days ago - QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 - Business Wire
- 14 days ago - QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel - Business Wire
- 4 weeks ago - Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis - Business Wire
- 5 weeks ago - Qiagen Announces Form 20-F Annual Report Filing for 2025 Results - Business Wire
- 5 weeks ago - QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention - Business Wire